Financial Services -
Banks - Diversified - NYSE - GB
$ 17.58
-0.453 %
$ 63.1 B
Market Cap
8.62
P/E
1. INTRINSIC VALUE
Balance Sheet
Barclays PLC
| Current Assets | 510 B |
| Cash & Short-Term Investments | 510 B |
| Receivables | 0 |
| Other Current Assets | 0 |
| Non-Current Assets | 1.01 |
| Long-Term Investments | 151 B |
| PP&E | 3.6 B |
| Other Non-Current Assets | 854 B |
| Current Liabilities | 664 B |
| Accounts Payable | 0 |
| Short-Term Debt | 0 |
| Other Current Liabilities | 664 B |
| Non-Current Liabilities | 782 B |
| Long-Term Debt | 186 B |
| Other Non-Current Liabilities | 596 B |
EFFICIENCY
Earnings Waterfall
Barclays PLC
| Revenue | 26.2 B |
| Cost Of Revenue | 25.4 B |
| Gross Profit | 24.2 B |
| Operating Expenses | 16 B |
| Operating Income | 10.3 B |
| Other Expenses | 2.16 B |
| Net Income | 8.11 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Barclays PLC
| Net Income | 8.11 B |
| Depreciation & Amortization | 1.7 B |
| Capital Expenditures | -1.57 B |
| Stock-Based Compensation | 0 |
| Change in Working Capital | -6.33 B |
| Others | -2.7 B |
| Free Cash Flow | 5.54 B |
Wall Street Analysts Price Targets
Barclays PLC
Wall Street analysts predict an average 1-year price target for BCS of $29 , with forecasts ranging from
a
low of
$29 to a high of $29 .
BCS Lowest Price Target
Wall Street Target
29 USD
64.96%
BCS Average Price Target
Wall Street Target
29 USD
64.96%
BCS Highest Price Target
Wall Street Target
29 USD
64.96%
4. DIVIDEND
ANALYSIS
1.91%
DIVIDEND YIELD
0.274 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Barclays PLC
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Barclays (BCS) Upgraded to Strong Buy: Here's Why
Barclays (BCS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
zacks.com
- 6 days ago
Leading analysts prefers Barclays and NatWest over Lloyds amid challenging UK bank outlook
JPMorgan has reiterated its preference for Barclays PLC (LSE:BARC) and NatWest Group PLC (LSE:NWG) over Lloyds Banking Group PLC (LSE:LLOY), highlighting key divergences in performance driven by shifting margins and evolving market dynamics. The investment bank underscores Barclays and NatWest as "overweight" recommendations, with Barclays notably termed "the cheapest bank in Europe".
proactiveinvestors.co.uk
- 1 week ago
Barclays raises S&P 500 target to 6,050, Fed meeting and rate cut outlook, automakers, and tariffs
Market Domination anchors Julie Hyman and Josh Lipton break down the latest financial news for June 16, 2025. Venu Krishna, Barclays head of US equity strategy discusses how markets typically ignore geopolitical risks.
youtube.com
- 1 week ago
Barclays Rises 32.3% YTD: Is it the Right Time to Buy the Stock?
BCS shares are up 32.3% YTD as cost cuts, capital redeployment and solid liquidity drive investor optimism. Is now a good buying opportunity?
zacks.com
- 2 weeks ago
Traeger, Inc. (NYSE:COOK) Shares Acquired by Two Sigma Investments LP
Two Sigma Investments LP lifted its stake in shares of Traeger, Inc. (NYSE:COOK – Free Report) by 32.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 123,931 shares of the company’s stock after acquiring an additional 30,539 shares during the period. Two Sigma Investments LP owned 0.09% of Traeger worth $296,000 as of its most recent SEC filing. A number of other large investors have also made changes to their positions in the stock. Graham Capital Management L.P. acquired a new stake in Traeger in the 4th quarter worth about $37,000. Two Sigma Securities LLC acquired a new stake in Traeger in the 4th quarter worth about $78,000. Bank of America Corp DE boosted its stake in Traeger by 36.6% in the 4th quarter. Bank of America Corp DE now owns 33,314 shares of the company’s stock worth $80,000 after buying an additional 8,933 shares during the last quarter. Deutsche Bank AG boosted its stake in Traeger by 231.8% in the 4th quarter. Deutsche Bank AG now owns 41,344 shares of the company’s stock worth $99,000 after buying an additional 28,883 shares during the last quarter. Finally, Barclays PLC boosted its stake in Traeger by 15.9% in the 4th quarter. Barclays PLC now owns 51,987 shares of the company’s stock worth $124,000 after buying an additional 7,126 shares during the last quarter. Institutional investors and hedge funds own 46.84% of the company’s stock. Analyst Ratings Changes A number of brokerages have issued reports on COOK. Royal Bank of Canada decreased their price target on Traeger from $2.75 to $2.00 and set a “sector perform” rating on the stock in a research note on Friday, March 7th. Robert W. Baird decreased their price target on Traeger from $3.50 to $2.50 and set a “neutral” rating on the stock in a research note on Friday, March 7th. Telsey Advisory Group decreased their price target on Traeger from $2.50 to $2.00 and set a “market perform” rating on the stock in a research note on Friday, May 2nd. Morgan Stanley cut their price objective on Traeger from $3.00 to $2.50 and set an “underweight” rating on the stock in a report on Friday, March 7th. Finally, Canaccord Genuity Group cut their price objective on Traeger from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Traeger currently has an average rating of “Hold” and a consensus price target of $2.44. Check Out Our Latest Research Report on Traeger Traeger Stock Performance Traeger stock opened at $1.85 on Wednesday. The stock’s 50 day moving average price is $1.45 and its 200 day moving average price is $2.08. The firm has a market capitalization of $251.16 million, a PE ratio of -4.63 and a beta of 1.38. The company has a debt-to-equity ratio of 1.42, a quick ratio of 1.08 and a current ratio of 2.09. Traeger, Inc. has a one year low of $1.28 and a one year high of $3.97. Insider Activity In related news, CEO Jeremy Andrus acquired 250,000 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was purchased at an average cost of $1.38 per share, for a total transaction of $345,000.00. Following the purchase, the chief executive officer now directly owns 14,052,354 shares in the company, valued at $19,392,248.52. This represents a 1.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders bought 730,387 shares of company stock worth $1,009,986. 14.70% of the stock is currently owned by insiders. Traeger Company Profile (Free Report) Traeger, Inc, together with its subsidiaries, designs, sources, sells, and supports wood pellet fueled barbecue grills for retailers, distributors, and direct to consumers in the United States. Its wood pellet grills are internet of things devices that allow owners to program, monitor, and control their grill through its Traeger app. See Also Five stocks we like better than Traeger Why Are These Companies Considered Blue Chips? AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway What to Know About Investing in Penny Stocks Casey’s Surges on Strong Q4, More Gains Likely Ahead Value Investing: Is it a Good Strategy in 2022? (Hint: Always) Government Mandate Sends eVTOL Stocks Flying Want to see what other hedge funds are holding COOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Traeger, Inc. (NYSE:COOK – Free Report).
https://www.defenseworld.net
- 2 weeks ago
Squarepoint Ops LLC Makes New $59,000 Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX)
Squarepoint Ops LLC purchased a new position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 19,461 shares of the company’s stock, valued at approximately $59,000. A number of other large investors also recently bought and sold shares of the stock. SG Americas Securities LLC raised its stake in TScan Therapeutics by 31.2% during the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock worth $62,000 after purchasing an additional 4,852 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock valued at $59,000 after acquiring an additional 5,694 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of TScan Therapeutics by 5.2% during the 4th quarter. Wellington Management Group LLP now owns 132,895 shares of the company’s stock valued at $404,000 after acquiring an additional 6,550 shares in the last quarter. Barclays PLC lifted its holdings in shares of TScan Therapeutics by 16.3% during the 4th quarter. Barclays PLC now owns 67,508 shares of the company’s stock valued at $206,000 after acquiring an additional 9,441 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new position in shares of TScan Therapeutics during the 4th quarter valued at $32,000. Hedge funds and other institutional investors own 82.83% of the company’s stock. TScan Therapeutics Price Performance TCRX opened at $1.69 on Wednesday. The company has a 50-day moving average of $1.43 and a 200-day moving average of $2.18. The company has a market capitalization of $95.64 million, a P/E ratio of -1.59 and a beta of 0.98. TScan Therapeutics, Inc. has a 1-year low of $1.02 and a 1-year high of $9.29. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.62 million. Equities analysts expect that TScan Therapeutics, Inc. will post -1.12 EPS for the current fiscal year. Analysts Set New Price Targets TCRX has been the topic of several recent research reports. HC Wainwright reduced their target price on shares of TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Wedbush restated an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, May 6th. Needham & Company LLC restated a “buy” rating and set a $9.00 target price on shares of TScan Therapeutics in a report on Tuesday, April 8th. Barclays reduced their target price on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $10.00 price target on shares of TScan Therapeutics in a research note on Friday, March 14th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $7.80. View Our Latest Research Report on TCRX Insider Activity at TScan Therapeutics In other news, major shareholder Lynx1 Capital Management Lp bought 1,200,000 shares of TScan Therapeutics stock in a transaction on Tuesday, May 20th. The stock was purchased at an average cost of $1.20 per share, with a total value of $1,440,000.00. Following the purchase, the insider now directly owns 7,946,141 shares of the company’s stock, valued at approximately $9,535,369.20. This trade represents a 17.79% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 4.35% of the company’s stock. TScan Therapeutics Profile (Free Report) TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
https://www.defenseworld.net
- 2 weeks ago
Squarepoint Ops LLC Decreases Position in Waldencast plc (NASDAQ:WALD)
Squarepoint Ops LLC decreased its stake in Waldencast plc (NASDAQ:WALD – Free Report) by 82.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,600 shares of the company’s stock after selling 78,847 shares during the period. Squarepoint Ops LLC’s holdings in Waldencast were worth $67,000 as of its most recent SEC filing. Several other institutional investors and hedge funds also recently modified their holdings of the stock. Barclays PLC boosted its holdings in Waldencast by 15.1% in the fourth quarter. Barclays PLC now owns 37,342 shares of the company’s stock valued at $150,000 after purchasing an additional 4,906 shares during the last quarter. SG Americas Securities LLC purchased a new position in Waldencast in the fourth quarter valued at about $42,000. Northern Trust Corp boosted its holdings in Waldencast by 4.1% in the fourth quarter. Northern Trust Corp now owns 167,662 shares of the company’s stock valued at $674,000 after purchasing an additional 6,640 shares during the last quarter. Ethic Inc. purchased a new position in Waldencast in the fourth quarter valued at about $56,000. Finally, Wells Fargo & Company MN boosted its holdings in Waldencast by 29.9% in the fourth quarter. Wells Fargo & Company MN now owns 14,571 shares of the company’s stock valued at $59,000 after purchasing an additional 3,358 shares during the last quarter. Hedge funds and other institutional investors own 41.97% of the company’s stock. Waldencast Stock Down 0.9% NASDAQ WALD opened at $2.30 on Wednesday. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.21. The stock’s 50 day moving average is $2.56 and its two-hundred day moving average is $3.06. Waldencast plc has a 1-year low of $1.98 and a 1-year high of $4.74. Analysts Set New Price Targets Several brokerages recently issued reports on WALD. Canaccord Genuity Group cut their price target on Waldencast from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, May 15th. Wall Street Zen downgraded Waldencast from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Telsey Advisory Group cut their price target on Waldencast from $5.00 to $4.00 and set an “outperform” rating on the stock in a report on Thursday, May 15th. Industrial Alliance Securities set a $5.00 price target on Waldencast in a report on Tuesday, April 22nd. Finally, Alliance Global Partners reissued a “buy” rating on shares of Waldencast in a report on Thursday, May 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Waldencast presently has an average rating of “Moderate Buy” and a consensus price target of $5.11. View Our Latest Stock Report on Waldencast Waldencast Company Profile (Free Report) Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians. Read More Five stocks we like better than Waldencast The 3 Best Blue-Chip Stocks to Buy Now AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Most Volatile Stocks, What Investors Need to Know Casey’s Surges on Strong Q4, More Gains Likely Ahead Health Care Stocks Explained: Why You Might Want to Invest Government Mandate Sends eVTOL Stocks Flying
https://www.defenseworld.net
- 2 weeks ago
Barclays Plans to Trim IB Workforce by More Than 200 to Reduce Costs
BCS intends to slash more than 200 investment banking roles as it reallocates resources toward high-growth trading and advisory areas.
zacks.com
- 2 weeks ago
3 Stocks to Watch From the Prospering Foreign Banks Industry
The Zacks Foreign Bank stocks like HSBC, IBN and BCS look set to benefit from core business focus and low rates despite global economic headwinds.
zacks.com
- 2 weeks ago
Tesla's fundamentals don't matter until it matters, says Barclays' Dan Levy
Dan Levy, Barclays senior equity research analyst, joins 'The Exchange' to discuss what's next for Tesla and the impact of Elon Musk's fallout with the president on the stock.
youtube.com
- 2 weeks ago
Are Barclays' Restructuring Efforts Key to Boosting Profitability?
BCS trims costs and shifts focus to core units, targeting 2 billion euros in gross savings by 2026 to drive long-term profitability.
zacks.com
- 2 weeks ago
The biggest risk to valuations is what happens to 10-year rates, says Barclays' Venu Krishna
Venu Krishna, Barclays head of U.S. Equity Strategy, joins 'The Exchange' to discuss Barclays lifting it S&P target to 6,050.
youtube.com
- 3 weeks ago
8. Profile
Summary
Barclays PLC BCS
COUNTRY
GB
INDUSTRY
Banks - Diversified
MARKET CAP
$ 63.1 B
Dividend Yield
1.91%
Description
Barclays PLC provides various financial services in the United Kingdom, Europe, the Americas, Africa, the Middle East, and Asia. The company operates through Barclays UK; Barclays UK Corporate Bank; Barclays Private Bank and Wealth Management; Barclays Investment Bank; and Barclays US Consumer Bank segments. It offers financial services, such as retail banking, credit cards, wholesale banking, investment banking, wealth management, and investment management services, as well as lending products. In addition, the company engages in securities dealing activities and issuing of credit cards. The company was formerly known as Barclays Bank public limited company and changed its name to Barclays PLC in January 1985. Barclays PLC was founded in 1690 and is headquartered in London, the United Kingdom.
Contact
1 Churchill Place, London, E14 5HP
https://home.barclays
IPO
Date
Sept. 9, 1986
Employees
93000
Officers
Ms. Angela Anna Cross
Group Finance Director & Executive Director
Mr. Craig Bright
Chief Information Officer
Mr. Reid Marsh
Global Chairman of Investment Banking & Acting Head of European Banking
Marco Valla
Global Head of Technology, Media & Telecoms and Consumer & Retail Investment Banking
Mr. Matthew Fitzwater
Group Chief Compliance Officer
Dr. Adam Kelleher
Chief Data Scientist for Research
Ms. Susannah Hall Parden
Group Chief Accounting Officer
Mr. Coimbatore Sundararajan Venkatakrishnan Ph.D.
Group Chief Executive Officer & Executive Director
Mr. Alistair Currie
Group Chief Operating Officer & Chief Executive of Barclays Execution Services (BX)
Mr. Stephen Victor Shapiro
Group General Counsel